key: cord-0786450-bh2sa83z
authors: Dickinson, Gordon M
title: Remdesivir – A giant step, or a tiptoe?()
date: 2020-05-13
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2020.05.015
sha: 65954602e2caaeec5ff77826b7158ed443fb4a94
doc_id: 786450
cord_uid: bh2sa83z

nan

Edited by Franco Rongioletti, MD and Leonard J Hoenig, MD The abrupt emergence and spread of, SARS-COV-2 has taken the world by surprise. There is a global search for treatment. One of the most promising is Remdesivir, a drug developed to treat ebola virus (it did not), that has not yet been fully studied. The preliminary reports indicate activity vs COVID-19 and some efficacy.

Remdesivir reminds one of other viruses and another drug. The AIDS epidemic also took the world by storm, first recognized in 1981 and without any "proven" treatment for several years. A drug, 3'-deoxy-3'-aido-thymidine, sitting on the shelves of the NCI since the 1960s when it failed as a chemotherapeutic agent against cancer, was tested, shown to have beneficial effects at shutting down HIV replication in the laboratory and in a limited trial. In 1986, a randomized clinical trial documented that it did stop HIV. This compound, named zidovudine, rapidly entered clinical use, although there were skeptics. Unfortunately, zidovudine was potentially toxic and its benefit was short lived as the HIV would escape control through mutation. But zidovudine did show the way, many other drugs followed, and in 1996, thanks to the benefit of new assays and laboratory tools to guide treatment, we were able to combine drugs and achieve lasting control of HIV. A different virus, a different epidemic, but a similar first step although as of this writing, we are unsure if this will end the lethal effects of covid-19 infection.

Remdesivir is a nucleoside analog of adenosine that was developed by a research team at Gilead searching for a treatment for Ebola virus. The drug did not work for Ebola, although the studies indicated it was a safe drug. Work with the corona viruses suggested activity in vitro and in monkeys, and we now have some anecdotal information and the initial human trials that suggest activity.

There are three studies now available:

1. a small randomized double-blind study performed in China and published in The Lancet that suggests minimal activity, but enough to recommend further studies. 2. a second study, reported by the company but not yet published that compared five days to ten days of remdesivir and showed no difference in outcome.

3. a third study, the randomized controlled Adaptive COVID-19 Treatment Trial, is reported to have reduced the time to recovery from 15 to 11 days and reduced the mortality rate from 11.6% to 8%. This preliminary data, most not yet published, have been deemed sufficient to allow the FDA approve its use in hospitalized patients.

Several reservations: 1. The efficacy as reported thus far is moderate at best. 2. The safety when given for a potentially fatal infection appears good.

3. The optimal time to use the drug is unclear. From our understanding of the covid19 disease is that its lethality often stems from an aggressive host response with a cytokine storm in which the host response kills the patient. One can reasonably posit that the time to use the drug is early in the infection before the patient is severely ill. But we do not know this. 4. The drug exists only in a form that must be given by intravenous infusion. This is acceptable for the ill hospitalized patient, but not so for the patient with minimal symptoms 5. Conversely, we presently have only a few other candidate antiviral drugs with potential.

As of May 5, 2020, Remdesivir appears to be a relatively safe drug that currently has been christened the standard or treatment for severe covid-19 disease, but whether it remains so is not at all clear. As was the case with zidovudine for HIV, it may be only the initial therapy that will be replaced by more effective regimens in the near future.

Clinical benefits of remdesivir in rhesus macaques infected with SARS-CoV-2

Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial

NIH /NAID report on the Adaptive COVID-19